Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments

Rhea-AI Summary

Arcutis (Nasdaq: ARQT) announced that professional golfer Max Homa joined its Free to Be Me awareness campaign to encourage people with seborrheic dermatitis to seek long-term treatment. The company highlights ZORYVE foam 0.3%, indicated for ages 9+, showing rapid clearance and itch relief in clinical trials.

In trials, 77% achieved clear/almost clear skin at 8 weeks versus 53% for inactive foam; itch relief reached nearly 63% versus 41%. ZORYVE is steroid-free, leave-in, and reported common side effects ≥1% (common cold, nausea, headache).

Positive

• 77% of patients achieved clear or almost clear skin at 8 weeks
• Nearly 63% achieved significant itch relief at Week 8
• ZORYVE indicated for adults and children 9 years and older

Negative

• Common side effects reported ≥1%: common cold (1.5%), nausea (1.3%), headache (1.1%)

Key Figures

Americans with seborrheic dermatitis: 10 million ZORYVE foam strength: 0.3% Clear or almost clear skin: 77% (458 individuals) +5 more

8 metrics

Americans with seborrheic dermatitis 10 million Prevalence mentioned for seborrheic dermatitis in the U.S.

ZORYVE foam strength 0.3% Roflumilast foam concentration for seborrheic dermatitis

Clear or almost clear skin 77% (458 individuals) ZORYVE foam users after 8 weeks in clinical trials

Control clear or almost clear 53% (225 people) Inactive foam group after 8 weeks in clinical trials

Itch relief with ZORYVE 63% (n=206) Individuals with significant itch relief at Week 8

Itch relief with control 41% (n=98) Individuals using foam without active ingredient at Week 8

Early itch improvement 48 hours Earliest reported itch improvement with ZORYVE in trials

Common cold incidence 1.5% Most common adverse event with ZORYVE foam 0.3%

Market Reality Check

Price: $26.98 Vol: Volume 1,154,360 is sligh...

normal vol

$26.98 Last Close

Volume Volume 1,154,360 is slightly below the 1,198,045 share 20-day average. normal

Technical Price at 26.31 is trading above the 200-day MA of 20.49 and below the 52-week high of 31.77.

Peers on Argus

ARQT gained 3.52% while several biotech peers also showed gains (e.g., TARS +5.8...

3 Up

ARQT gained 3.52% while several biotech peers also showed gains (e.g., TARS +5.84%, AGIO +3.11%, IRON +3.26%, TVTX +3.02%, APGE +1.26%). Momentum scanner also flagged BEAM, TARS, and DNLI moving up, but sector momentum was not classified as a coordinated move.

Common Catalyst Some peers reported conference participation today, suggesting a mix of company-specific and sector-related drivers rather than a single unifying catalyst.

Historical Context

5 past events · Latest: 2026-02-05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-02-05	Inducement RSU grants	Neutral	+4.8%	Reported 94,000 RSUs granted to 12 new hires under inducement plan.
2026-02-02	Clinical trial results	Positive	+0.8%	Positive Phase 2 INTEGUMENT-INFANT topline data for ZORYVE cream 0.05%.
2026-01-26	Promotion agreement change	Neutral	+0.5%	Termination of Kowa promotion deal; Arcutis taking over PCP/pediatric promotion.
2026-01-22	Earnings and conferences	Neutral	-1.7%	Announcement of Q4/FY 2025 earnings date and Guggenheim conference appearance.
2026-01-21	Survey on steroids	Positive	+3.2%	Nationwide survey underscoring concern with topical steroids and long-term needs.

Pattern Detected

Recent ARQT news, especially clinical and strategic updates, has generally coincided with modest positive moves, with only one recent neutral scheduling update followed by a mild decline.

Recent Company History

Over the past months, Arcutis has reported several developments around ZORYVE and broader dermatology positioning. A Jan 21, 2026 survey release highlighting unmet needs in chronic inflammatory skin disease coincided with a +3.21% move. Positive INTEGUMENT-INFANT Phase 2 data for ZORYVE cream on Feb 2, 2026 saw a smaller +0.79% reaction. Operational items like inducement RSU grants on Feb 5, 2026 and the Kowa promotion termination have also aligned with modest gains, while an earnings-date announcement on Jan 22, 2026 was followed by a -1.69% move. Today’s awareness campaign continues the theme of strengthening ZORYVE’s dermatology footprint.

Market Pulse Summary

This announcement expands Arcutis’s dermatology franchise visibility by pairing Max Homa’s story wit...

Analysis

This announcement expands Arcutis’s dermatology franchise visibility by pairing Max Homa’s story with clinical data for ZORYVE foam 0.3%. The release highlights substantial response rates, including 77% achieving clear or almost clear skin and 63% with significant itch relief at Week 8, plus early improvements within 48 hours. In context of prior ZORYVE updates and survey data, investors may watch future prescriptions, real‑world safety consistent with the reported ≥1% adverse events, and upcoming financial disclosures to gauge commercial traction.

Key Terms

seborrheic dermatitis

1 terms

seborrheic dermatitis medical

"10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease"

Seborrheic dermatitis is a common, chronic skin condition that causes red, flaky, itchy patches where oil-producing glands are concentrated, such as the scalp, face and chest. Investors care because it creates steady demand for over-the-counter and prescription treatments, influences clinical trial and regulatory risk for new therapies, and can affect sales, reimbursement and market share in dermatology—think of it as a recurring household problem that sustains a health-care product market.

AI-generated analysis. Not financial advice.

• Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms
• ZORYVE^® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas
• 10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalp
  

WESTLAKE VILLAGE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that six-time PGA Tour winner Max Homa has joined the company’s Free to Be Me awareness campaign to help encourage the millions of Americans living with seborrheic dermatitis (seb derm) to speak with their healthcare providers about long-term treatment options.

Like many people with seb derm, Max Homa spent years trying to understand what was happening to his skin. He often scrolled through the internet trying to self-diagnose what was causing his dry, flaky, and itchy face and scalp. He also tried countless over-the-counter treatments, but nothing helped his symptoms or provided long-term relief. By joining the Free to Be Me campaign, Max hopes that his story will encourage people to speak with their doctor to identify and properly treat their seb derm.

“Even on the days when my face wasn’t red or flaky, seb derm was in the back of my mind—I’d catch myself wondering if other people could see it,” said Max Homa, husband, father, and professional golfer. “I spent years trying different products, but without a diagnosis, nothing worked. Getting a proper diagnosis and treating my seb derm with ZORYVE made a big difference. Having clearer skin and scalp has allowed me to fully focus on what matters most to me.”

A Media Snippet accompanying this announcement is available by clicking on this link.

“Seborrheic dermatitis is a chronic, recurrent inflammatory skin disease causing flaking, redness, and persistent itching, which can significantly impact a person’s quality of life due to the emotional toll that comes with a highly noticeable condition,” said Dr. Tina Bhutani, a board-certified dermatologist, clinical researcher, and CEO of Synergy Dermatology. “Many patients, like Max, spend years trying to self-diagnose or manage symptoms on their own, often assuming the problem is ‘just dandruff,’ not realizing their discomfort comes from a medical condition that can be effectively treated by a dermatologist. Because seb derm is lifelong, it’s essential to have effective, safe, and well-tolerated treatments for regular and long-term use. ZORYVE is a unique treatment option because it is a steroid-free topical foam that can be used anywhere on the body, including the scalp, face, and beard, to provide meaningful, sustained relief and help patients regain comfort and confidence in their skin.”

ZORYVE foam 0.3% is indicated for the treatment of seborrheic dermatitis in adults and children 9 years of age and older. ZORYVE is uniquely formulated as a water-based foam without sensitizers or irritants that can disrupt the skin barrier or damage hair. ZORYVE is a non-greasy, leave-in foam that is suitable for all skin and hair types. In clinical trials, ZORYVE foam provides rapid skin clearance and significant reduction in itch, with 77% of the 458 individuals using ZORYVE foam achieving clear or almost clear skin after 8 weeks of treatment, compared to 53% of the 225 people using inactive foam.

In one clinical trial, nearly 63% of individuals treated with ZORYVE foam (n=206) achieved significant itch relief at Week 8, compared to almost 41% who used a foam without the active ingredient (n=98). Itch improvement with ZORYVE was seen early, with some individuals reporting improvement in 48 hours.

ZORYVE foam is safe and well tolerated. The most common side effects (≥1%) with ZORYVE foam 0.3% for seborrheic dermatitis are common cold (1.5%), nausea (1.3%), and headache (1.1%). The adverse event profiles of ZORYVE foam in the long-term studies with up to a year of treatment were consistent with those seen in the clinical studies.

For more information on ZORYVE foam, including full prescribing information, please visit ZORYVE.com.

About ZORYVE^®
ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined—atopic dermatitis, seborrheic dermatitis, and plaque psoriasis.  ZORYVE foam is a topical formulation of roflumilast, an advanced targeted topical phosphodiesterase type 4 (PDE4) inhibitor. Inhibiting PDE4, an intracellular enzyme that is an established target in dermatology, decreases the production of pro-inflammatory mediators. This decreases inflammation in the skin and balances the skin’s immune system.

Demonstrating both clinical impact and broad industry recognition, ZORYVE has been honored with multiple prestigious awards and recommendations. ZORYVE was recently awarded by Allure with the "2025 Best of Beauty Breakthrough Award," making it the first FDA-approved medication for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis to win this prominent award. ZORYVE cream 0.3% and ZORYVE foam 0.3% were also awarded the National Psoriasis Foundation’s Seal of Recognition—the first FDA-approved prescription brand to receive the honor. In 2024, ZORYVE cream 0.15% was awarded Glamour’s Beauty and Wellness Award for “Best Eczema Product.” Additionally, the American Academy of Dermatology (AAD) issued a strong recommendation for the use of ZORYVE cream 0.15% in adult patients with mild to moderate atopic dermatitis, according to updated guidelines released in June 2025.

About Free to Be Me
The Free to Be Me campaign shares real experiences of people with inflammatory skin conditions—including atopic dermatitis, plaque psoriasis, and seborrheic dermatitis—to help others feel seen, understood, and empowered to take the important step of starting an open conversation with a healthcare provider to find a safe and effective treatment plan.

INDICATION
ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential of ZORYVE foam to simplify disease management for care of seborrheic dermatitis, and the potential of real-world use results of ZORYVE on individual patients. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com

Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com

FAQ

What did Arcutis (ARQT) announce on February 24, 2026 about Max Homa?

Max Homa joined Arcutis' Free to Be Me campaign to raise awareness of seborrheic dermatitis and encourage doctor conversations. According to the company, the effort highlights long-term treatment options including ZORYVE foam 0.3% for skin and scalp.

How effective was ZORYVE (ARQT) in clinical trials for seborrheic dermatitis at 8 weeks?

ZORYVE achieved clear or almost clear skin in 77% of treated individuals at 8 weeks, versus 53% with inactive foam. According to the company, trials also showed rapid itch reduction and early improvements for some patients within 48 hours.

Is ZORYVE foam (ARQT) approved for children and what ages are covered?

ZORYVE foam 0.3% is indicated for adults and children aged 9 years and older. According to the company, the formulation is steroid-free, leave-in, and suitable for use on scalp, face, beard, and other hair-bearing areas.

What common side effects did Arcutis (ARQT) report for ZORYVE foam in trials?

The most common side effects (≥1%) were common cold (1.5%), nausea (1.3%), and headache (1.1%). According to the company, long-term study adverse event profiles were consistent with those seen in clinical studies up to a year.

What should investors consider about Arcutis' (ARQT) marketing of ZORYVE with a celebrity campaign?

Celebrity endorsement may raise public awareness and potentially increase product uptake by encouraging diagnoses and prescriptions. According to the company, the campaign aims to prompt patient‑provider conversations about long‑term seborrheic dermatitis treatment options.